GLP-1 RAs Deliver Attenuated Weight Loss in Breast Cancer Patients on Endocrine Therapy; Semaglutide, Tirzepatide Outperform
GLP-1 receptor agonist-associated weight loss in breast cancer patients receiving concurrent endocrine therapy: a retrospective cohort analysis.
Abstract
GLP-1 RAs achieved only 4.5% mean weight loss over one year in breast cancer patients on endocrine therapy, significantly less than typical trial results, with semaglutide and tirzepatide performing best.
TitrateLab articles covering Tirzepatide
Written by TitrateLab, separately from the study summarized above.
